THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.

(Please scan this QR code to view the RHP)

MODERN® Diagnostic & Research Centre

MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED

CIN: U85110DL2012PLC234368

Our Company was originally incorporated as "Modern Diagnostic & Research Centre Private Limited" as a private limited company, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated April 16, 2012 issued by Registrar of Companies, Delhi having Corporate Identification Number U85110DL2012PTC234368. Subsequently, our Company was converted from a private limited company to public limited company pursuant to special resolution passed in the Extra-Ordinary General Meeting of the company held on November 16, 2024 and consequently the name of our Company was changed to "Modern Diagnostic & Research Centre Limited" pursuant to fresh certificate of incorporation dated December 18, 2024 issued to our Company by the Registrar of Companies, Central Processing Centre having Corporate Identification Number U85110DL2012PLC234368. For details of change in name and registered office of our Company, please refer to chapter titled *"History and Corporate Matters"* beginning on page no. 139 of the Red Herring Prospectus.

Registered Office: Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India

Corporate Office: 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Website:** www.mdrcindia.com; **E-Mail:** compliance@mdrcindia.com; Telephone No: +91 9999474297

Company Secretary and Compliance Officer: Mrs. Priyanshu Yadav

PROMOTERS OF OUR COMPANY: MR. DEVENDRA SINGH YADAV, MRS. DEEPALI YADAV, MRS ASHA YADAV AND MR. JITENDRA SINGH

THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 40,99,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED ("MDRC" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [•] LAKHS ("THE ISSUE"), OF WHICH 2,06,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•]/- LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 38,92,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.15% AND 25.78%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION: NOT APPLICABLE

PRICE BAND: ₹ 85/- TO ₹ 90/-PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH.

THE FLOOR PRICE IS 8.50 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 9.00 TIMES OF THE FACE VALUE.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE IS 10.43 TIMES AND AT THE CAP PRICE IS 11.04 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 3200 EQUITY SHARES AND IN MULTIPLES OF 1600 EQUITY SHARES THEREAFTER.

ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: TUESDAY, DECEMBER 30, 2025

BID/ISSUE OPENS ON: WEDNESDAY, DECEMBER 31, 2025

BID/ISSUE CLOSES ON: FRIDAY, JANUARY 02, 2026

BRIEF DESCRIPTION OF THE ISSUER COMPANY

Our company is a services provider in diagnostic and related healthcare tests services in India. We offer a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through our integrated, nationwide network, we offer a complete range of diagnostic facilities in radiology and pathology. We provide healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Our customers include individual patients, hospitals and other healthcare providers and corporate customers. Presently, we have 21 centres which includes 18 laboratories and 3 diagnostics centres in 8 states. We offer wide range of diagnostic facilities in Radiology and High-end Pathology. Our healthcare tests and services include Ultrasound and colour doppler, CT scan, MRI, Digital X-ray, Mammography, Heart lab, Neuro lab and laboratory, ECG, CBCT, OPG, PFT etc.

THE ISSUE IS BEING MADE THROUGH THE BOOK BUILDING PROCESS IN TERMS OF REGULATION 229(2) AND 253(1) OF CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED FROM TIME TO TIME. (INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES).

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME"). BSE LIMITED SHALL BE THE DESIGNATED STOCK EXCHANGE.

QIB Portion: Not more than 50% of the Net Issue | Non-Institutional Portion: Not less than 15% of the Net Issue | Individual Investor Portion: Not less than 35% of the Net Issue | Market Maker Portion 2,06,400 Equity Shares or 5.04% of the Issue

For further details, please refer chapter titled "Terms of The Issue" beginning on Page No. 211 of the Red Herring Prospectus.

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISK FACTORS INVOLVED AND MUST NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER. IN RELATION TO PRICE BAND, POTENTIAL INVESTORS SHOULD ONLY REFER TO THIS PRE-ISSUE AND PRICE BAND ADVERTISEMENT FOR THE ISSUE AND SHOULD NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION AVAILABLE IN ANY MANNER IN RELATION TO THE VALUATION OF THE COMPANY AS THESE ARE NOT ENDORSED, PUBLISHED OR CONFIRMED EITHER BY THE COMPANY OR BRLM.

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated December 23, 2025, the above provided price band is justified based on quantitative factors/ KPIs disclosed in the 'Basis for Issue Price' section beginning on page 86 of the Red Herring Prospectus vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in 'Basis for Issue Price' section beginning on page 86 of the Red Herring Prospectus and provided below in the advertisement.

RISKS TO INVESTORS:

1. Risk to investors: Summary Description of key Risk Factors Based on Materiality (For further details, please refer to Section titled "Risk Factors" on page 23 of RHP)

1. *Any interruptions at our laboratories and diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.*
2. *Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.*
3. *Majority of our operations are concentrated in state of Haryana and any adverse developments affecting Haryana could have an adverse effect on our business, results of operations and financial condition.*
4. *We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.*
5. *There may be significant dependence on key diagnostic equipment and core technology infrastructure, the failure of which could result in serious service disruptions.*
6. *Our heavy reliance on pathology services as the primary revenue driver presents significant risks that could negatively impact our operations, financial performance, and long-term growth prospects.*
7. *Failure to attract and retain skilled healthcare professionals and experienced technical staff may lead to compromised diagnostic service quality and negatively impact patient care delivery.*
8. *We have experienced negative cash flows in the past. Any such negative cash flows in the future could affect our business, results of operations and prospects.*
9. *We require certain approvals, licenses, registrations and permits to operate our business, and failure to obtain or renew them in a timely manner or maintain the statutory and regulatory permits and approvals required to operate our business may adversely affect our operations and financial conditions.*
10. *Our Restated Financial Statements are prepared and signed by the Peer Review Auditor who is not Statutory Auditor of our Company as required under the provisions of ICDR.*

2. Details for suitable ratio of the company and its peer group for the year ended March 31, 2025.

Name of the company	Standalone / Consolidated	Face Value (₹)	EPS (₹) Basic	P/E Ratio	RoNW (%)	NAV per Equity Share (₹)	Revenue from operations(₹ in Lakhs)
Modern Diagnostics & Research Centre Limited	Standalone	10.00	8.15	[•]	43.27%	18.84	7,794.54
Peer Group							
Vijaya Diagnostic Centre Limited	Consolidated	1.00	13.92	72.36	18.07%	77.42	68,139.01

Source: *All the financial information for listed industry peer mentioned above is on a consolidated basis sourced from the Annual Reports/Information of the peer company uploaded on the NSE and BSE website for the year ended March 31, 2025.*

Notes:

1. *P/E Ratio has been computed based on the closing market price of equity shares on the NSE on March 28, 2025 divided by the Diluted EPS of March 31, 2025.*
2. *RoNW is computed as net profit after tax divided by the closing net worth. Net worth has been computed as sum of share capital and reserves and surplus.*
3. *NAV is computed as the closing net worth divided by the closing outstanding number of equity shares adjusted for corporate actions, if any.*

3. Weighted Average return on net worth for the last 3 FYs, and return on net worth for any interim period for the issuer company.

Financial Year/Period	Return on Net Worth (%)	Weights
Financial Year ended March 31, 2025	43.27	3
Financial Year ended March 31, 2024	49.28	2
Financial Year ended March 31, 2023	(96.12)	1
Weighted Average	**22.04**	**6**
For the Stub Period ended on June 30, 2025*	**12.64**	

** Not Annualized*

Notes:

1. *Weighted Average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. sum of (RoNW × Weight) for each year / Total of weights;*
2. *The figures disclosed above are based on the Restated Financial Statements of our Company.*
3. *Net worth, as restated at the end of the relevant financial year/period, is equity attributable to the owners of the Company.*

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI, as applicable.
The Price per share of our Company based on the primary / new issue of shares (equity / convertible securities).

a) The Price per share of our Company based on the primary/ new issue of shares (equity / convertible securities).
There has been no issuance of Equity Shares during the 18 months preceding the date of the Red Herring Prospectus (Except Bonus Issue of Shares), where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale / acquisition of shares (equity / convertible securities).
There have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

c) Price per share based on the last five primary or secondary transactions;
Since there are no transactions to report to under (a) and (b) therefore, information based on last 5 secondary transactions (primary transactions and secondary transaction where Promoter / Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of this Red Herring Prospectus irrespective of the size of transactions is required to be disclosed. Details of the same is provided below:

Primary Transaction:

Date of Issue	Nature of Allotment	Names of Person	Number of Shares Allotted	Issue Price
February 24, 2025	Bonus Allotment	Mr. Devendra Singh Yadav	84,00,000	0.00
		Mrs. Asha Yadav	5,00,000	
		Mr. Nitin Kumar	5,00,000	
		Mrs. Deepali Yadav	5,00,000	
		Mrs. Sunita Yadav	99,980	
		Mr. Garvit Garg	10	
		Mr. Pulkit Garg	10	
	TOTAL		**1,00,00,000**	**0.00**
	Weighted Average Cost of Acquisition (WACA)			**0.00**

d) Weighted average cost of acquisition, floor price and cap price:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Floor Price i.e. ₹ 85/-	Cap Price i.e. ₹ 90/-
Weighted average cost of acquisition of primary / new issue as per paragraph a above.	N.A.	N.A.	N.A.
Weighted average cost of acquisition for secondary sale / acquisition as per paragraph b above.	N.A.	N.A.	N.A.
Weighted average cost of acquisition of primary issuances / secondary transactions as per paragraph 8(c) above: - Primary Transaction - Secondary Transaction	0.00 N.A.	0.00 N.A.	0.00 N.A.

Justification for Basis of Issue price: -

The following provides a detailed explanation for the Issue Price/Cap Price being 0.00 times of weighted average cost of acquisition of Equity Shares that were issued by our Company or acquired or sold by our Promoter, Promoter Group, or other shareholders with rights to nominate directors on our Board by way of primary and secondary transactions in the last three full Calendar Years preceding the date of the Red Herring Prospectus compared to our Company's KPIs/ financial ratios for the Calendar Years 2025, 2024 and 2023 and in view of external factors, if any.

- The Indian healthcare sector renowned for its dynamic growth potential and diverse components was estimated to value at an impressive USD 216 billion in FY23. This sector is projected to nearly double to an estimated USD 454 billion by FY28, representing a robust compound annual growth rate of 16%.
- The revenue growth from FY 2023 to FY 2025 reflects a compounded annual growth rate (CAGR) of 11.47%.
- The Price Band is ₹ 85 to ₹ 90 per Equity share has been determined by our Company, in consultation with the BRLM, on the basis of the demand from investors for the Equity Shares through the Book Building process. Investors should read the abovementioned information along with *"Risk Factors"*, *"Business Overview"* and *"Summary of Financial Information"* beginning on pages 23, 108, and 47 respectively of the Red Herring Prospectus, to have a more informed view.

Continue From Next Page...

Continue From Previous Page...

ADDITIONAL INFORMATION FOR INVESTORS: This will include the following:

1. Details of proposed /undertaken pre-issue placements from the DRHP filing date: Not Applicable.
2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date: Not Applicable.
3. ***Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company.***

	Pre-Issue shareholding as at the date of Advertisement			Post-Issue shareholding as at Allotment			
	Shareholders	Number of Equity Shares	Shareholding (in%)*	At the lower end of the price band (₹ 85/-)		At the upper end of the price band (₹ 90/-)	
				Number of Equity Shares	Share holding (in%)#	Number of Equity Shares	Share holding (in %)#
Promoters:							
1.	Mr. Devendra Singh Yadav	92,40,000	84.00	92,40,000	61.20	92,40,000	61.20
	Mrs. Deepali Yadav	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mrs. Asha Yadav	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mr. Jitendra Singh	Nil	Nil	Nil	Nil	Nil	Nil
	TOTAL A	**1,03,40,000**	**94.00**	**1,03,40,000**	**68.48**	**1,03,40,000**	**68.48**
Promoter's Group:							
2.	Mr. Nitin Kumar	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mrs. Sunita Yadav	1,09,978	1.00	1,09,978	0.73	1,09,978	0.73
	TOTAL B	**6,59,978**	**6.00**	**6,59,978**	**4.37**	**6,59,978**	**4.37**
	Total Promoters and Promoter Group Shareholding (A+B)	**1,09,99,978**	**99.99**	**1,09,99,978**	**72.85**	**1,09,99,978**	**72.85**
Top 10 shareholders (Other than Promoters and Promoter Group)							
1.	Mr. Garvit Garg	11	Negligible	11	Negligible	11	Negligible
2.	Mr. Pulkit Garg	11	Negligible	11	Negligible	11	Negligible
3.	Public in IPO	-	-	40,99,200	27.15	40,99,200	27.15
	TOTAL C	**22**	**0.00**	**40,99,222**	**27.15**	**40,99,222**	**27.15**
	TOTAL (A+B+C)	**1,10,00,000**	**100.00**	**1,50,99,200**	**100.00**	**1,50,99,200**	**100.00**

**As a % of Pre-Issued Capital*
#As a % of Post Issued Capital

Notes:

1. *The Promoter Group shareholders are as mentioned in Point No.02*
2. *Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.*
3. *Based on the Issue price of ₹ [•] and subject to finalization of the basis of allotment.*

BASIS FOR THE ISSUE PRICE

The ***"Basis of the issue price"*** on page 86 of the offer document has been updated with the above price band. Please refer to the website of the BRLM for the "Basis of the issue price" updated with the above price band. You can scan the QR code given on the first page of this advertisement for the chapter titled ***"Basis for the Issue Price"*** on page 86 of the Red Herring Prospectus.

INDICATIVE TIMELINE FOR THE ISSUE

Submission of Bids (Other than Bids from Anchor Investors)
• No investor shall be permitted to bid at cut off price. • No investor shall be permitted downgrade, modification and cancellation of their bids.

BID / ISSUE PROGRAM

Anchor Investor Bidding Date		Tuesday, December 30, 2025	
Bid Opening Date	**Wednesday, December 31, 2025**	**Initiation of Unblocking of Funds/refunds (T +2 Days)**	**On or before Tuesday, January 06, 2026**
Bid Closing Date (T day)	**Friday, January 02, 2026**	**Credit of Equity Shares to demat accounts of Allotees (T +2 Days)**	**On or before Tuesday, January 06, 2026**
Finalization of basis of allotment with the Designated Stock Exchange/ Allotment of Securities (T +1 Day)	**Monday, January 05, 2026**	**Commencement of Trading of Equity Shares on the Stock Exchanges/Listing Date (T + 3 Days)**	**On or before Wednesday, January 07, 2026**

Timelines for Submission / Uploading of Application/Bid

Application Submission by Investors

- For all physical applications: Between 10.00 a.m. and 5.00 p.m. during Issue Period (except the Bid Closing Date).
- Electronic Applications (Online ASBA through 3-in-1 accounts): Up to 4.00 p.m. on Bid Closing Date i.e. T day.
- Electronic Applications (Bank ASBA through online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA, etc.): Up to 3.00 p.m. on Bid Closing Date i.e. T day.
- Electronic Applications (Syndicate Non-Retail, Non-Individual Applications): Up to 3.00 p.m. on Bid Closing Date i.e. T day.
- Physical Applications (Bank ASBA): Up to 1.00 p.m. on Bid Closing Date i.e. T Day.
- Physical Applications (Syndicate Non-Retail, Non-Individual Applications of QIBs and NIIs): Up to 12.00 p.m. on Bid Closing Date i.e. T Day and Syndicate members shall transfer such applications to banks before 1.00 p.m. on Bid Closing Date i.e. T Day.
- On the Bid Closing Date, the Bids shall be uploaded until 4.00 p.m. for all Bidders.
- Bid modification: From Issue Opening Date up to 4.00 p.m. on Bid Closing Date i.e. T Day.
- UPI mandate acceptance/confirmation end time shall be at 5.00 p.m. on the Issue/Bid Closing Date.

Above information is only for reference purpose only and may change from bank to bank and broker to broker. Investors are requested to contact their own bank/broker for specific details.

ASBA* | **Simple, Safe, Smart way of Application- Make use of it!!!** | ***Applications Supported by Blocked Amount (ASBA) is a better way of applying to issue by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below. Mandatory in Public Issues No cheque will be accepted.**

UPI — UNITED PAYMENTS INTERFACE

UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to Rs. 500,000**
Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. "ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 222 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.
**ASBA forms can be downloaded from the website BSE and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in.*
***List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. IndusInd Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll-free number-18001201740 and Mail Id- ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in.*

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS:
For information on the main objects and other objects of our Company, see *"History and Corporate Structure"* on page 139 of the Red Herring Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section *"Material Contracts and Documents for Inspection"* on page 284 of the Red Herring Prospectus.

LIABILITY OF MEMBERS OF THE COMPANY: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorised share capital of the Company is ₹ 17,00,00,000 divided into 1,70,00,000 Equity Shares of face value of ₹ 10/- each. The issued, subscribed and paid-up share capital of the Company before the Issue is ₹ 11,00,00,000 divided into 1,10,00,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see "Capital Structure" on the page 60 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Mr. Devendra Singh Yadav – 5000 and Mrs. Asha Yadav – 5000. For details of the Capital Structure, see "Capital Structure" on the page 60 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus/ Prospectus will be filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 202 of the RHP.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited ("BSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by BSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to page 203 of the Red Herring Prospectus for the full text of the Disclaimer clause pertaining to BSE.

CREDIT RATING: This being the issue of Equity Shares, no credit rating is required.

DEBENTURE TRUSTEE: This being the issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since this issue is made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading Agency.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of our Company and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to 'Risk Factors' on page 23 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
BEELINE	MUFG	MODERN Diagnostic & Research Centre
BEELINE CAPITAL ADVISORS PRIVATE LIMITED **SEBI Registration Number:** INM000012917 **Address:** B 1311-1314, Thirteenth Floor, Shilp Corporate Park, Rajpath Rangoli Road, Thaltej, Ahmadabad-380054, Gujarat, India. **Telephone Number:** 07948407357 **Email Id:** mb@beelinemb.com **Investors Grievance Id:** ig@beelinemb.com **Website:** www.beelinemb.com **Contact Person:** Mr. Nikhil Shah **CIN:** U67190GJ2020PTC114322	**MUFG Intime India Private Limited (Formerly Link intime India Private Limited)** **SEBI Registration Number:** INR000004058 **Address:** C 101, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, India **Tel. No.:** +91-22-4918 6000/ +91 8108114949 **Email Id:** moderndiagnostic.smeipo@in.mpms.mufg.com Investors Grievance Id: moderndiagnostic.smeipo@in.mpms.mufg.com **Website:** www.linkintime.co.in **Contact Person:** Shanti Gopalkrishnan **CIN:** U67190MH1999PTC118368	**MODERN DIAGNOSTIC & RESEARCH LIMITED** Mrs. Priyanshu Yadav **Registered Office:** Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India **Corporate Office:** 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Telephone No:** +91- 9999474297 **E-Mail:** compliance@mdrcindia.com **Website:** www.mdrcindia.com Investors can contact the Company Secretary and Compliance Officer or the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE Limited i.e. www.bseindia.com, respectively.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE Limited i.e. www.bseindia.com, respectively.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered and Corporate Office of the Company: Modern Diagnostic & Research Centre Limited, Telephone: +91 9999474297; BRLM: Beeline Capital Advisors Private Limited, Telephone: +91-7948407357 and the Syndicate Member: Spread X Securities Private Limited; Telephone: +91 79 69072020 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of BSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

SYNDICATE MEMBER: Spread X Securities Private Limited

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK AND REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: IndusInd Bank Limited.

SPONSOR BANKS: IndusInd Bank Limited..

UPI: UPI Bidders can also bid through UPI mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

On behalf of Board of Directors
For, Modern Diagnostic & Research Centre Limited
sd/-
Mr. Devendra Singh Yadav
Chairman cum Managing Director

Place: Delhi
Date: December 23, 2025

Disclaimer: Modern Diagnostic & Research Centre Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the RHP with the Registrar of Companies, Delhi on December 23, 2025 and thereafter with SEBI and the Stock Exchanges. The RHP is available on the websites of SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE SME i.e. www.bseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 23 of the Red Herring Prospectus.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being Offered and sold outside the United States in 'offshore transactions' in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such Offers and sales are made. There will be no public offering in the United States.

THE BUSINESS DAILY
FINANCIAL EXPRESS
Read to Lead
FOR DAILY BUSINESS
INDIAN EXPRESS GROUP

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.

(Please scan this QR code to view the RHP)

MODERN® Diagnostic & Research Centre

MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED

CIN: U85110DL2012PLC234368

Our Company was originally incorporated as "Modern Diagnostic & Research Centre Private Limited" as a private limited company, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated April 16, 2012 issued by Registrar of Companies, Delhi having Corporate Identification Number U85110DL2012PTC234368. Subsequently, our Company was converted from a private limited company to public limited company pursuant to special resolution passed in the Extra-Ordinary General Meeting of the company held on November 16, 2024 and consequently the name of our Company was changed to "Modern Diagnostic & Research Centre Limited" pursuant to fresh certificate of incorporation dated December 18, 2024 issued to our Company by the Registrar of Companies, Central Processing Centre having Corporate Identification Number U85110DL2012PLC234368. For details of change in name and registered office of our Company, please refer to chapter titled *"History and Corporate Matters"* beginning on page no. 139 of the Red Herring Prospectus.

Registered Office: Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India

Corporate Office: 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Website:** www.mdrcindia.com; **E-Mail:** compliance@mdrcindia.com; Telephone No: +91 9999474297

Company Secretary and Compliance Officer: Mrs. Priyanshu Yadav

PROMOTERS OF OUR COMPANY: MR. DEVENDRA SINGH YADAV, MRS. DEEPALI YADAV, MRS ASHA YADAV AND MR. JITENDRA SINGH

THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 40,99,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED ("MDRC" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [•] LAKHS ("THE ISSUE"), OF WHICH 2,06,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•]/- LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 38,92,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.15% AND 25.78%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION: NOT APPLICABLE

PRICE BAND: ₹ 85/- TO ₹ 90/-PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH.

THE FLOOR PRICE IS 8.50 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 9.00 TIMES OF THE FACE VALUE.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE IS 10.43 TIMES AND AT THE CAP PRICE IS 11.04 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 3200 EQUITY SHARES AND IN MULTIPLES OF 1600 EQUITY SHARES THEREAFTER.

ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: TUESDAY, DECEMBER 30, 2025

BID/ISSUE OPENS ON: WEDNESDAY, DECEMBER 31, 2025

BID/ISSUE CLOSES ON: FRIDAY, JANUARY 02, 2026

BRIEF DESCRIPTION OF THE ISSUER COMPANY

Our company is a services provider in diagnostic and related healthcare tests services in India. We offer a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through our integrated, nationwide network, we offer a complete range of diagnostic facilities in radiology and pathology. We provide healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Our customers include individual patients, hospitals and other healthcare providers and corporate customers. Presently, we have 21 centres which includes 18 laboratories and 3 diagnostics centres in 8 states. We offer wide range of diagnostic facilities in Radiology and High-end Pathology. Our healthcare tests and services include Ultrasound and colour doppler, CT scan, MRI, Digital X-ray, Mammography, Heart lab, Neuro lab and laboratory, ECG, CBCT, OPG, PFT etc.

THE ISSUE IS BEING MADE THROUGH THE BOOK BUILDING PROCESS IN TERMS OF REGULATION 229(2) AND 253(1) OF CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED FROM TIME TO TIME. (INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES).

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME"). BSE LIMITED SHALL BE THE DESIGNATED STOCK EXCHANGE.

QIB Portion: Not more than 50% of the Net Issue | Non-Institutional Portion: Not less than 15% of the Net Issue | Individual Investor Portion: Not less than 35% of the Net Issue | Market Maker Portion 2,06,400 Equity Shares or 5.04% of the Issue

For further details, please refer chapter titled "Terms of The Issue" beginning on Page No. 211 of the Red Herring Prospectus.

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISK FACTORS INVOLVED AND MUST NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER. IN RELATION TO PRICE BAND, POTENTIAL INVESTORS SHOULD ONLY REFER TO THIS PRE-ISSUE AND PRICE BAND ADVERTISEMENT FOR THE ISSUE AND SHOULD NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION AVAILABLE IN ANY MANNER IN RELATION TO THE VALUATION OF THE COMPANY AS THESE ARE NOT ENDORSED, PUBLISHED OR CONFIRMED EITHER BY THE COMPANY OR BRLM.

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated December 23, 2025, the above provided price band is justified based on quantitative factors/ KPIs disclosed in the 'Basis for Issue Price' section beginning on page 86 of the Red Herring Prospectus vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in 'Basis for Issue Price' section beginning on page 86 of the Red Herring Prospectus and provided below in the advertisement.

RISKS TO INVESTORS:

1. Risk to investors: Summary Description of key Risk Factors Based on Materiality (For further details, please refer to Section titled "Risk Factors" on page 23 of RHP)

1. *Any interruptions at our laboratories and diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.*
2. *Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.*
3. *Majority of our operations are concentrated in state of Haryana and any adverse developments affecting Haryana could have an adverse effect on our business, results of operations and financial condition.*
4. *We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.*
5. *There may be significant dependence on key diagnostic equipment and core technology infrastructure, the failure of which could result in serious service disruptions.*
6. *Our heavy reliance on pathology services as the primary revenue driver presents significant risks that could negatively impact our operations, financial performance, and long-term growth prospects.*
7. *Failure to attract and retain skilled healthcare professionals and experienced technical staff may lead to compromised diagnostic service quality and negatively impact patient care delivery.*
8. *We have experienced negative cash flows in the past. Any such negative cash flows in the future could affect our business, results of operations and prospects.*
9. *We require certain approvals, licenses, registrations and permits to operate our business, and failure to obtain or renew them in a timely manner or maintain the statutory and regulatory permits and approvals required to operate our business may adversely affect our operations and financial conditions.*
10. *Our Restated Financial Statements are prepared and signed by the Peer Review Auditor who is not Statutory Auditor of our Company as required under the provisions of ICDR.*

2. Details for suitable ratio of the company and its peer group for the year ended March 31, 2025.

Name of the company	Standalone / Consolidated	Face Value (₹)	EPS (₹) Basic	P/E Ratio	RoNW (%)	NAV per Equity Share (₹)	Revenue from operations(₹ in Lakhs)
Modern Diagnostics & Research Centre Limited	Standalone	10.00	8.15	[•]	43.27%	18.84	7,794.54
Peer Group							
Vijaya Diagnostic Centre Limited	Consolidated	1.00	13.92	72.36	18.07%	77.42	68,139.01

Source: *All the financial information for listed industry peer mentioned above is on a consolidated basis sourced from the Annual Reports/Information of the peer company uploaded on the NSE and BSE website for the year ended March 31, 2025.*

Notes:

1. *P/E Ratio has been computed based on the closing market price of equity shares on the NSE on March 28, 2025 divided by the Diluted EPS of March 31, 2025.*
2. *RoNW is computed as net profit after tax divided by the closing net worth. Net worth has been computed as sum of share capital and reserves and surplus.*
3. *NAV is computed as the closing net worth divided by the closing outstanding number of equity shares adjusted for corporate actions, if any.*

3. Weighted Average return on net worth for the last 3 FYs, and return on net worth for any interim period for the issuer company.

Financial Year/Period	Return on Net Worth (%)	Weights
Financial Year ended March 31, 2025	43.27	3
Financial Year ended March 31, 2024	49.28	2
Financial Year ended March 31, 2023	(96.12)	1
Weighted Average	**22.04**	**6**
For the Stub Period ended on June 30, 2025*	**12.64**	

** Not Annualized*

Notes:

1. *Weighted Average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. sum of (RoNW × Weight) for each year / Total of weights;*
2. *The figures disclosed above are based on the Restated Financial Statements of our Company.*
3. *Net worth, as restated at the end of the relevant financial year/period, is equity attributable to the owners of the Company.*

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI, as applicable.
The Price per share of our Company based on the primary / new issue of shares (equity / convertible securities).

a) The Price per share of our Company based on the primary/ new issue of shares (equity / convertible securities).
There has been no issuance of Equity Shares during the 18 months preceding the date of the Red Herring Prospectus (Except Bonus Issue of Shares), where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale / acquisition of shares (equity / convertible securities).
There have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

c) Price per share based on the last five primary or secondary transactions;
Since there are no transactions to report to under (a) and (b) therefore, information based on last 5 secondary transactions (primary transactions and secondary transaction where Promoter / Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of this Red Herring Prospectus irrespective of the size of transactions is required to be disclosed. Details of the same is provided below:

Primary Transaction:

Date of Issue	Nature of Allotment	Names of Person	Number of Shares Allotted	Issue Price
February 24, 2025	Bonus Allotment	Mr. Devendra Singh Yadav	84,00,000	0.00
		Mrs. Asha Yadav	5,00,000	
		Mr. Nitin Kumar	5,00,000	
		Mrs. Deepali Yadav	5,00,000	
		Mrs. Sunita Yadav	99,980	
		Mr. Garvit Garg	10	
		Mr. Pulkit Garg	10	
	TOTAL		**1,00,00,000**	**0.00**
	Weighted Average Cost of Acquisition (WACA)			**0.00**

d) Weighted average cost of acquisition, floor price and cap price:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Floor Price i.e. ₹ 85/-	Cap Price i.e. ₹ 90/-
Weighted average cost of acquisition of primary / new issue as per paragraph a above.	N.A.	N.A.	N.A.
Weighted average cost of acquisition for secondary sale / acquisition as per paragraph b above.	N.A.	N.A.	N.A.
Weighted average cost of acquisition of primary issuances / secondary transactions as per paragraph 8(c) above: - Primary Transaction - Secondary Transaction	0.00 N.A.	0.00 N.A.	0.00 N.A.

Justification for Basis of Issue price: -

The following provides a detailed explanation for the Issue Price/Cap Price being 0.00 times of weighted average cost of acquisition of Equity Shares that were issued by our Company or acquired or sold by our Promoter, Promoter Group, or other shareholders with rights to nominate directors on our Board by way of primary and secondary transactions in the last three full Calendar Years preceding the date of the Red Herring Prospectus compared to our Company's KPIs/ financial ratios for the Calendar Years 2025, 2024 and 2023 and in view of external factors, if any.

- The Indian healthcare sector renowned for its dynamic growth potential and diverse components was estimated to value at an impressive USD 216 billion in FY23. This sector is projected to nearly double to an estimated USD 454 billion by FY28, representing a robust compound annual growth rate of 16%.
- The revenue growth from FY 2023 to FY 2025 reflects a compounded annual growth rate (CAGR) of 11.47%.
- The Price Band is ₹ 85 to ₹ 90 per Equity share has been determined by our Company, in consultation with the BRLM, on the basis of the demand from investors for the Equity Shares through the Book Building process. Investors should read the abovementioned information along with *"Risk Factors"*, *"Business Overview"* and *"Summary of Financial Information"* beginning on pages 23, 108, and 47 respectively of the Red Herring Prospectus, to have a more informed view.

Continue From Next Page...

Continue From Previous Page...

ADDITIONAL INFORMATION FOR INVESTORS: This will include the following:

1. Details of proposed /undertaken pre-issue placements from the DRHP filing date: Not Applicable.
2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date: Not Applicable.
3. ***Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company.***

	Pre-Issue shareholding as at the date of Advertisement			Post-Issue shareholding as at Allotment			
	Shareholders	Number of Equity Shares	Shareholding (in%)*	At the lower end of the price band (₹ 85/-)		At the upper end of the price band (₹ 90/-)	
				Number of Equity Shares	Share holding (in%)#	Number of Equity Shares	Share holding (in %)#
Promoters:							
1.	Mr. Devendra Singh Yadav	92,40,000	84.00	92,40,000	61.20	92,40,000	61.20
	Mrs. Deepali Yadav	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mrs. Asha Yadav	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mr. Jitendra Singh	Nil	Nil	Nil	Nil	Nil	Nil
	TOTAL A	**1,03,40,000**	**94.00**	**1,03,40,000**	**68.48**	**1,03,40,000**	**68.48**
Promoter's Group:							
2.	Mr. Nitin Kumar	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mrs. Sunita Yadav	1,09,978	1.00	1,09,978	0.73	1,09,978	0.73
	TOTAL B	**6,59,978**	**6.00**	**6,59,978**	**4.37**	**6,59,978**	**4.37**
	Total Promoters and Promoter Group Shareholding (A+B)	**1,09,99,978**	**99.99**	**1,09,99,978**	**72.85**	**1,09,99,978**	**72.85**
Top 10 shareholders (Other than Promoters and Promoter Group)							
1.	Mr. Garvit Garg	11	Negligible	11	Negligible	11	Negligible
2.	Mr. Pulkit Garg	11	Negligible	11	Negligible	11	Negligible
3.	Public in IPO	-	-	40,99,200	27.15	40,99,200	27.15
	TOTAL C	**22**	**0.00**	**40,99,222**	**27.15**	**40,99,222**	**27.15**
	TOTAL (A+B+C)	**1,10,00,000**	**100.00**	**1,50,99,200**	**100.00**	**1,50,99,200**	**100.00**

**As a % of Pre-Issued Capital*
#As a % of Post Issued Capital

Notes:

1. *The Promoter Group shareholders are as mentioned in Point No.02*
2. *Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.*
3. *Based on the Issue price of ₹ [•] and subject to finalization of the basis of allotment.*

BASIS FOR THE ISSUE PRICE

The ***"Basis of the issue price"*** on page 86 of the offer document has been updated with the above price band. Please refer to the website of the BRLM for the "Basis of the issue price" updated with the above price band. You can scan the QR code given on the first page of this advertisement for the chapter titled ***"Basis for the Issue Price"*** on page 86 of the Red Herring Prospectus.

INDICATIVE TIMELINE FOR THE ISSUE

Submission of Bids (Other than Bids from Anchor Investors)
• No investor shall be permitted to bid at cut off price. • No investor shall be permitted downgrade, modification and cancellation of their bids.

BID / ISSUE PROGRAM

Anchor Investor Bidding Date		Tuesday, December 30, 2025	
Bid Opening Date	**Wednesday, December 31, 2025**	**Initiation of Unblocking of Funds/refunds (T +2 Days)**	**On or before Tuesday, January 06, 2026**
Bid Closing Date (T day)	**Friday, January 02, 2026**	**Credit of Equity Shares to demat accounts of Allotees (T +2 Days)**	**On or before Tuesday, January 06, 2026**
Finalization of basis of allotment with the Designated Stock Exchange/ Allotment of Securities (T +1 Day)	**Monday, January 05, 2026**	**Commencement of Trading of Equity Shares on the Stock Exchanges/Listing Date (T + 3 Days)**	**On or before Wednesday, January 07, 2026**

Timelines for Submission / Uploading of Application/Bid

Application Submission by Investors

- For all physical applications: Between 10.00 a.m. and 5.00 p.m. during Issue Period (except the Bid Closing Date).
- Electronic Applications (Online ASBA through 3-in-1 accounts): Up to 4.00 p.m. on Bid Closing Date i.e. T day.
- Electronic Applications (Bank ASBA through online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA, etc.): Up to 3.00 p.m. on Bid Closing Date i.e. T day.
- Electronic Applications (Syndicate Non-Retail, Non-Individual Applications): Up to 3.00 p.m. on Bid Closing Date i.e. T day.
- Physical Applications (Bank ASBA): Up to 1.00 p.m. on Bid Closing Date i.e. T Day.
- Physical Applications (Syndicate Non-Retail, Non-Individual Applications of QIBs and NIIs): Up to 12.00 p.m. on Bid Closing Date i.e. T Day and Syndicate members shall transfer such applications to banks before 1.00 p.m. on Bid Closing Date i.e. T Day.
- On the Bid Closing Date, the Bids shall be uploaded until 4.00 p.m. for all Bidders.
- Bid modification: From Issue Opening Date up to 4.00 p.m. on Bid Closing Date i.e. T Day.
- UPI mandate acceptance/confirmation end time shall be at 5.00 p.m. on the Issue/Bid Closing Date.

Above information is only for reference purpose only and may change from bank to bank and broker to broker. Investors are requested to contact their own bank/broker for specific details.

ASBA* | **Simple, Safe, Smart way of Application- Make use of it!!!** | ***Applications Supported by Blocked Amount (ASBA) is a better way of applying to issue by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below. Mandatory in Public Issues No cheque will be accepted.**

UPI - UNITED PAYMENTS INTERFACE

UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to Rs. 500,000**
Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. "ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 222 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.
**ASBA forms can be downloaded from the website BSE and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in.*
***List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. IndusInd Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll-free number-18001201740 and Mail Id- ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in.*

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS:
For information on the main objects and other objects of our Company, see *"History and Corporate Structure"* on page 139 of the Red Herring Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section *"Material Contracts and Documents for Inspection"* on page 284 of the Red Herring Prospectus.

LIABILITY OF MEMBERS OF THE COMPANY: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorised share capital of the Company is ₹ 17,00,00,000 divided into 1,70,00,000 Equity Shares of face value of ₹ 10/- each. The issued, subscribed and paid-up share capital of the Company before the Issue is ₹ 11,00,00,000 divided into 1,10,00,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see "Capital Structure" on the page 60 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Mr. Devendra Singh Yadav – 5000 and Mrs. Asha Yadav – 5000. For details of the Capital Structure, see "Capital Structure" on the page 60 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus/ Prospectus will be filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 202 of the RHP.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited ("BSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by BSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to page 203 of the Red Herring Prospectus for the full text of the Disclaimer clause pertaining to BSE.

CREDIT RATING: This being the issue of Equity Shares, no credit rating is required.

DEBENTURE TRUSTEE: This being the issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since this issue is made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading Agency.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of our Company and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to 'Risk Factors' on page 23 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
BEELINE	MUFG	MODERN Diagnostic & Research Centre
BEELINE CAPITAL ADVISORS PRIVATE LIMITED **SEBI Registration Number:** INM000012917 **Address:** B 1311-1314, Thirteenth Floor, Shilp Corporate Park, Rajpath Rangoli Road, Thaltej, Ahmadabad-380054, Gujarat, India. **Telephone Number:** 07948407357 **Email Id:** mb@beelinemb.com **Investors Grievance Id:** ig@beelinemb.com **Website:** www.beelinemb.com **Contact Person:** Mr. Nikhil Shah **CIN:** U67190GJ2020PTC114322	**MUFG Intime India Private Limited (Formerly Link intime India Private Limited)** **SEBI Registration Number:** INR000004058 **Address:** C 101, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, India **Tel. No.:** +91-22-4918 6000/ +91 8108114949 **Email Id:** moderndiagnostic.smeipo@in.mpms.mufg.com Investors Grievance Id: moderndiagnostic.smeipo@in.mpms.mufg.com **Website:** www.linkintime.co.in **Contact Person:** Shanti Gopalkrishnan **CIN:** U67190MH1999PTC118368	**MODERN DIAGNOSTIC & RESEARCH LIMITED** Mrs. Priyanshu Yadav **Registered Office:** Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India **Corporate Office:** 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Telephone No:** +91-9999474297 **E-Mail:** compliance@mdrcindia.com **Website:** www.mdrcindia.com Investors can contact the Company Secretary and Compliance Officer or the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE Limited i.e. www.bseindia.com, respectively.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE Limited i.e. www.bseindia.com, respectively.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered and Corporate Office of the Company: Modern Diagnostic & Research Centre Limited, Telephone: +91 9999474297; BRLM: Beeline Capital Advisors Private Limited, Telephone: +91-7948407357 and the Syndicate Member: Spread X Securities Private Limited; Telephone: +91 79 69072020 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of BSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

SYNDICATE MEMBER: Spread X Securities Private Limited

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK AND REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: IndusInd Bank Limited.

SPONSOR BANKS: IndusInd Bank Limited..

UPI: UPI Bidders can also bid through UPI mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

On behalf of Board of Directors
For, Modern Diagnostic & Research Centre Limited
sd/-
Mr. Devendra Singh Yadav
Chairman cum Managing Director

Place: Delhi
Date: December 23, 2025

Disclaimer: Modern Diagnostic & Research Centre Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the RHP with the Registrar of Companies, Delhi on December 23, 2025 and thereafter with SEBI and the Stock Exchanges. The RHP is available on the websites of SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE SME i.e. www.bseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 23 of the Red Herring Prospectus.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being Offered and sold outside the United States in 'offshore transactions' in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such Offers and sales are made. There will be no public offering in the United States.

SMFG Grihashakti
Nayi Asha. Naya Vishwas.

एसएमएफजी इंडिया होम फाइनेंस कंपनी लिमिटेड

कॉर्पोरेट ऑफिस: 503 और 504, 5वीं मंजिल, जी–ब्लॉक, इंसपायार बीकेसी, बीकेसीमेनरोड, बांद्रा कुर्ला कॉम्प्लेक्स, बांद्रा (ई), मुंबई–400 051 रजि. **ऑफिस:** कॉमर्सोन आईटी पार्क, टॉवर बी, प्रथम तल, नंबर 111, माउंट पूनमल्ली रोड, पोरुर, चेन्नई – 600116, टीएन

अचल संपत्तियों की बिक्री हेतु बिक्री सूचना

वित्तीय आस्तियों के प्रतिभूतिकरण एवं पुनर्निर्माण तथा प्रतिभूति हित प्रवर्तन अधिनियम, 2002 के नियम 8(6) के प्रावधान के साथ पठित, प्रतिभूति हित (प्रवर्तन) नियम, 2002 के अंतर्गत अचल आस्तियों की बिक्री के लिए 30 दिनों की ई–नीलामी बिक्री सूचना।
एततद्वारा आम जनता को तथा विशेष रूप से ऋणी(ओं) और गारंटर(ओं) को सूचित किया जाता है कि नीचे सूचीबद्ध अचल संपत्तियां (''सुरक्षित परिसंपत्तियां'') जो सुरक्षित ऋणदाता के पास बंधक/प्रभारित हैं, जिनका कब्जा एसएमएफजी इंडिया होम फाइनेंस कंपनी लिमिटेड (जिसे आगे एसएमएचएफसी कहा जाएगा) (''सुरक्षित ऋणदाता'') के प्राधिकृत अधिकारी द्वारा ले लिया गया है, उन्हें नीचे उल्लिखित तिथि और समय पर ''जैसा है'', ''जैसा है'' और ''जो कुछ भी है'' के आधार पर बेचा जाएगा, ताकि नीचे उल्लिखित ऋणी(ओं) और गारंटर(ओं) से एसएमएचएफसी सुरक्षित ऋणदाता को देय नीचे उल्लिखित बकाया राशि और वसूली की तिथि तक उस पर ब्याज और अन्य व्यय की वसूली की जा सके।

क्र. सं.	उधारकर्ता (ओं)/ गारंटर (ओं) के नाम लैन	संपत्तियों का विवरण	आरक्षित मूल्य : / बयाना राशि जमा :	ई–नीलामी की तिथि एवं समय	ईएमडी जमा करने की तिथि
1.	लैन नंबर – 609139511684647 1. आकाश कुमार विश्वास पुत्र सुवाष विश्वास 2. ज्योति शरम	प्रॉपर्टी नंबर 143–ए, जिसका एरिया 49 वर्ग गज है, खसरा नंबर 39/3/22 में, सुंदर पार्क शास्त्री नगर के लेआउट में, गांव खुरेजी खास, इलाका शाहदरा दिल्ली–110031 में स्थित है, उस पर दूसरी और तीसरी मंजिल के साथ छत बनाने का अधिकार।	रु. 29,00,000/– रु. 2,90,000/–	02.02.2026 सुबह 11:00 बजे से दोपहर 01:00 बजे	31.01.2026

बिक्री के विवरण नियम और शर्तें नीचे दी गई हैं और विवरण हमारी/सुरक्षित लेनदार की वेबसाइट पर भी उपलब्ध कराए गए हैं।निम्नलिखित लिंक वेबसाइट का पता (;**https://BidDeal.in** और **and https://www.grihashakti.com/pdf/E-Auction.pdf).** पर भी दिए गए है।
इच्छुक बोलीदाता निम्नलिखित से आशीष कौशल, उनके मोबाइल नं. 8527134222, **ई–मेल : Ashish.Kaushal@ grihashakti.com**, और श्री निलोय डे, उनके मोबाइल नंबर 8655619157, , ई–मेलः **Niloy.Dey@grihashakti.com** भी संपर्क कर सकते हैं:

स्थान : दिल्ली **हस्ता/–प्राधिकृत अधिकारी,**
दिनांकः 22.12.2025 **एसएमएफजी इंडिया होम फाइनेंस कंपनी लिमिटेड**

प्रपत्रा संख्या आईएनसी–26
[कम्पनी (निगमन) नियमावली, 2014 के नियम 30 के अनुपालन में]
कंपनी के पंजीकृत कार्यालय को एक राज्य से दूसरे राज्य में बदलने के लिए समाचार पत्र में विज्ञापन प्रकाशित किया जाएगा
क्षेत्रीय निदेशक, उत्तरी क्षेत्रा के समक्ष
कंपनी अधिनियम, 2013 की धारा 13(4) के अनुसार
तथा
मेसर्स एमएमए डिजाइन प्राइवेट लिमिटेड जिसका पंजीकृत कार्यालय DCG2-0715, यूनिट नंबर 0715 टावर–2, डीएलएफ कॉर्पोरेट ग्रीन्स, सेक्टर 74,–A, गुड़गांव, हरियाणा, भारत, 122001, में है के मामले में

एतद्द्वारा आम जनता को सूचित दिया जाता है कि कंपनी अपने पंजीकृत कार्यालय को "आरओसी दिल्ली" से "आरओसी बैंगलोर" में उसके पंजीकृत कार्यालय को दूसरे राज्य में परिवर्तित करने के लिए कंपनी को सक्षम बनाने के लिए 08 जुलाई, 2024 को आयोजित असाधारण आम बैठक में पारित विशेष प्रस्ताव के संदर्भ में कंपनी के मेमोरेंडम ऑफ एसोसिएशन में परिवर्तन की पुष्टि के लिए कंपनी अधिनियम, 2013 की धारा 12, 13(4) के तहत क्षेत्रीय निदेशक, उत्तरी क्षेत्र को आवेदन करने का प्रस्ताव करती है।
किसी व्यक्ति का हित प्रस्तावित परिवर्तन से प्रभावित होने की संभावना है, तो वह व्यक्ति एमसीए पोर्टल (www.mca.gov.in) में शिकायत दर्ज कर सकता है या एक शपथ पत्र जिसमें उसके हित का प्रकार और उसके विरोध का कारण उल्लेखित हो, के साथ अपना/अपनी आपत्ति को इस सूचना के प्रकाशन की तारीख से 14 दिनों के भीतर क्षेत्रीय निदेशक, दिल्ली, बी–2 विंग, दूसरी मंजिल, पर्यावरण भवन, सीजीओ कॉम्प्लेक्स, नई दिल्ली–110003 पते पर पंजीकृत डाक द्वारा भेज सकते हैं और इसकी प्रति अवेदक कंपनी को उनके उपरोक्त पंजीकृत कार्यालय के पते पर भी भेजें।
पंजीकृत कार्यालय का पता: DCG2-0715, यूनिट नंबर 0715 टावर–2, डीएलएफ कॉर्पोरेट ग्रीन्स, सेक्टर 74,–A, गुड़गांव, हरियाणा, भारत, 122001 (वर्तमान पता)

आवेदक की ओर से ओर उसके लिए
हस्ता./– **हस्ता./–**
चित्तेश गुप्ता **पंकज मित्तल**
डीन: 07006503 **डीन: 06892118**
दिनांक: 23.12.2025

सार्वजनिक सूचना

यह सर्वसाधारण को सूचित किया जाता है कि एबीबी इंडिया लिमिटेड, जिसका पंजीकृत कार्यालय तृतीय तल, प्लॉट नं. 5 एवं 6, द्वितीय चरण, पीण्या औद्योगिक क्षेत्र–IV, बेंगलुरु, कर्नाटक–560058 में स्थित है, के निम्नलिखित शेयर प्रमाणपत्र पंजीकृत धारक द्वारा खो दिए गए हैं।
नामः राज कमल गुप्ता
फोलियो नंबरः R0010178
प्रमाणपत्र नंबरः 149571 से 149578
डिस्टिंक्टिव नंबरः 30181200 से 30181345
शेयरों की संख्याः 146
अंकित मूल्य (फेस वैल्यू): ₹10 प्रति शेयर
सार्वजनिक को सूचित किया जाता है कि उपर्युक्त शेयर प्रमाणपत्रों को खरीदने या किसी भी प्रकार से लेन–देन करने से सावधान रहें।
यदि किसी व्यक्ति का उपर्युक्त शेयर प्रमाणपत्र/प्रमाणपत्रों के संबंध में कोई दावा हो, तो वह इस सूचना के प्रकाशन की तिथि से 15 दिनों के भीतर कंपनी अथवा इसके आरटीए केफिन टेक्नोलॉजीज लिमिटेड, कार्वी सेलेनियम टावर–B, प्लॉट नं. 31–32, गाचीबोवली, फाइनेंशियल डिस्ट्रिक्ट, नानकरामगुड़ा, हैदराबाद, तेलंगाना –500032 के समक्ष अपना दावा प्रस्तुत करे। निर्धारित अवधि के पश्चात कोई भी दावा स्वीकार नहीं किया जाएगा और कंपनी डुप्लीकेट शेयर प्रमाणपत्र जारी करने की कार्यवाही करेगी।
स्थानः नई दिल्ली
दिनांकः 24.12.2025
शेयरधारक का नामः राज कमल गुप्ता

सार्वजनिक सूचना

आम जनता को सूचित किया जाता है कि आइशर मोटर्स लिमिटेड (सीआईएन : L34102DL1982PLC129877) के नीचे बताए गए इक्विटी शेयरों के मूल शेयर सर्टिफिकेट, जिसका रजिस्टर्ड ऑफिस ऑफिस नंबर 1111, 11वीं मंजिल, अशोका एस्टेट, प्लॉट नंबर 24, बाराखंभा रोड, नई दिल्ली, दिल्ली–110001 पर है, खो गए/गुम हो गए/नष्ट हो गए हैं और काफी खोजने के बाद भी नहीं मिल रहे हैं। रजिस्टर्ड धारक ने कंपनी से डुप्लीकेट शेयर सर्टिफिकेट जारी करने के लिए आवेदन किया है।
खोए हुए शेयर सर्टिफिकेट का विवरण इस प्रकार है:

शेयरधारकों का नाम	फोलियो नंबर	सर्टिफिकेट नंबर	विशिष्ट नंबर	शेयरों की संख्या
नीता ढींगरा और सुषमा ढींगरा	0014145	24150	2413101–2413200	100
		52635	10249147–10249246	100
		52636	10249247–10249276	30
		52637	10249277–10249281	5

कोई भी व्यक्ति जिसका उक्त शेयर सर्टिफिकेट के संबंध में कोई दावा या आपत्ति है, उसे इस नोटिस के प्रकाशन की तारीख से 15 दिनों के भीतर कंपनी के ऊपर बताए गए रजिस्टर्ड ऑफिस के पते पर, या इसके रजिस्ट्रार और शेयर ट्रांसफर एजेंट (आरटीए), एमयूएफजी इंटाइम इंडिया प्राइवेट लिमिटेड, के कार्यालयः सी –101, 247 पार्क, एलबीएस मार्ग, विक्रोली (पश्चिम), मुंबई–400083 पर अपना दावा या आपत्ति दर्ज करानी चाहिए। यदि निर्धारित समय अवधि के भीतर कोई दावा या आपत्ति प्राप्त नहीं होती है, तो कंपनी बिना किसी अन्य सूचना के उपरोक्त आवेदक को डुप्लीकेट शेयर सर्टिफिकेट जारी करने की प्रक्रिया आगे बढ़ाएगी, और उसके बाद कोई दावा स्वीकार नहीं किया जाएगा। जनता को सलाह दी जाती है कि वे मूल शेयर प्रमाणपत्रों के साथ किसी भी तरह का लेन–देन न करें।

आइशर मोटर्स लिमिटेड के लिए
दिनांक : 24.12.2025 **हस्ता./–**
स्थान: दिल्ली **[अधिकृत हस्ताक्षरकर्ता/कंपनी सेक्रेटरी]**

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.

MODERN®
Diagnostic & Research Centre

(Please scan this QR code to view the RHP)

MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED

CIN: U85110DL2012PLC234368

Our Company was originally incorporated as "Modern Diagnostic & Research Centre Private Limited" as a private limited company, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated April 16, 2012 issued by Registrar of Companies, Delhi having Corporate Identification Number U85110DL2012PTC234368. Subsequently, our Company was converted from a private limited company to public limited company pursuant to special resolution passed in the Extra-Ordinary General Meeting of the company held on November 16, 2024 and consequently the name of our Company was changed to "Modern Diagnostic & Research Centre Limited" pursuant to fresh certificate of incorporation dated December 18, 2024 issued to our Company by the Registrar of Companies, Central Processing Centre having Corporate Identification Number U85110DL2012PLC234368. For details of change in name and registered office of our Company, please refer to chapter titled *"History and Corporate Matters"* beginning on page no. 139 of the Red Herring Prospectus.

Registered Office: Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India

Corporate Office: 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Website:** www.mdrcindia.com; **E-Mail:** compliance@mdrcindia.com; Telephone No: +91 9999474297

Company Secretary and Compliance Officer: Mrs. Priyanshu Yadav

PROMOTERS OF OUR COMPANY: MR. DEVENDRA SINGH YADAV, MRS. DEEPALI YADAV, MRS ASHA YADAV AND MR. JITENDRA SINGH

THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 40,99,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED ("MDRC" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [•] LAKHS ("THE ISSUE"), OF WHICH 2,06,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•]/- LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 38,92,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [•]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•]/- PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.15% AND 25.78%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION: NOT APPLICABLE

PRICE BAND: ₹ 85/- TO ₹ 90/-PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH.
THE FLOOR PRICE IS 8.50 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 9.00 TIMES OF THE FACE VALUE.
THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FISCAL 2025 AT THE FLOOR PRICE IS 10.43 TIMES AND AT THE CAP PRICE IS 11.04 TIMES.
BIDS CAN BE MADE FOR A MINIMUM OF 3200 EQUITY SHARES AND IN MULTIPLES OF 1600 EQUITY SHARES THEREAFTER.

ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE: TUESDAY, DECEMBER 30, 2025
BID/ISSUE OPENS ON: WEDNESDAY, DECEMBER 31, 2025
BID/ISSUE CLOSES ON: FRIDAY, JANUARY 02, 2026

BRIEF DESCRIPTION OF THE ISSUER COMPANY

Our company is a services provider in diagnostic and related healthcare tests services in India. We offer a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through our integrated, nationwide network, we offer a complete range of diagnostic facilities in radiology and pathology. We provide healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Our customers include individual patients, hospitals and other healthcare providers and corporate customers. Presently, we have 21 centres which includes 18 laboratories and 3 diagnostics centres in 8 states. We offer wide range of diagnostic facilities in Radiology and High-end Pathology. Our healthcare tests and services include Ultrasound and colour doppler, CT scan, MRI, Digital X-ray, Mammography, Heart lab, Neuro lab and laboratory, ECG, CBCT, OPG, PFT etc.

THE ISSUE IS BEING MADE THROUGH THE BOOK BUILDING PROCESS IN TERMS OF REGULATION 229(2) AND 253(1) OF CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED FROM TIME TO TIME. (INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES).

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME"). BSE LIMITED SHALL BE THE DESIGNATED STOCK EXCHANGE.

QIB Portion: Not more than 50% of the Net Issue | Non-Institutional Portion: Not less than 15% of the Net Issue | Individual Investor Portion: Not less than 35% of the Net Issue | Market Maker Portion 2,06,400 Equity Shares or 5.04% of the Issue

For further details, please refer chapter titled "Terms of The Issue" beginning on Page No. 211 of the Red Herring Prospectus.

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RED HERRING PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISK FACTORS INVOLVED AND MUST NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER. IN RELATION TO PRICE BAND, POTENTIAL INVESTORS SHOULD ONLY REFER TO THIS PRE-ISSUE AND PRICE BAND ADVERTISEMENT FOR THE ISSUE AND SHOULD NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION AVAILABLE IN ANY MANNER IN RELATION TO THE VALUATION OF THE COMPANY AS THESE ARE NOT ENDORSED, PUBLISHED OR CONFIRMED EITHER BY THE COMPANY OR BRLM.

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated December 23, 2025, the above provided price band is justified based on quantitative factors/ KPIs disclosed in the 'Basis for Issue Price' section beginning on page 86 of the Red Herring Prospectus vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in 'Basis for Issue Price' section beginning on page 86 of the Red Herring Prospectus and provided below in the advertisement.

RISKS TO INVESTORS:

1. Risk to investors: Summary Description of key Risk Factors Based on Materiality (For further details, please refer to Section titled "Risk Factors" on page 23 of RHP)

1. *Any interruptions at our laboratories and diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.*
2. *Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.*
3. *Majority of our operations are concentrated in state of Haryana and any adverse developments affecting Haryana could have an adverse effect on our business, results of operations and financial condition.*
4. *We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.*
5. *There may be significant dependence on key diagnostic equipment and core technology infrastructure, the failure of which could result in serious service disruptions.*
6. *Our heavy reliance on pathology services as the primary revenue driver presents significant risks that could negatively impact our operations, financial performance, and long-term growth prospects.*
7. *Failure to attract and retain skilled healthcare professionals and experienced technical staff may lead to compromised diagnostic service quality and negatively impact patient care delivery.*
8. *We have experienced negative cash flows in the past. Any such negative cash flows in the future could affect our business, results of operations and prospects.*
9. *We require certain approvals, licenses, registrations and permits to operate our business, and failure to obtain or renew them in a timely manner or maintain the statutory and regulatory permits and approvals required to operate our business may adversely affect our operations and financial conditions.*
10. *Our Restated Financial Statements are prepared and signed by the Peer Review Auditor who is not Statutory Auditor of our Company as required under the provisions of ICDR.*

2. Details for suitable ratio of the company and its peer group for the year ended March 31, 2025.

Name of the company	Standalone / Consolidated	Face Value (₹)	EPS (₹) Basic	P/E Ratio	RoNW (%)	NAV per Equity Share (₹)	Revenue from operations(₹ in Lakhs)
Modern Diagnostics & Research Centre Limited	Standalone	10.00	8.15	[•]	43.27%	18.84	7,794.54
Peer Group							
Vijaya Diagnostic Centre Limited	Consolidated	1.00	13.92	72.36	18.07%	77.42	68,139.01

Source: *All the financial information for listed industry peer mentioned above is on a consolidated basis sourced from the Annual Reports/Information of the peer company uploaded on the NSE and BSE website for the year ended March 31, 2025.*

Notes:

1. *P/E Ratio has been computed based on the closing market price of equity shares on the NSE on March 28, 2025 divided by the Diluted EPS of March 31, 2025.*
2. *RoNW is computed as net profit after tax divided by the closing net worth. Net worth has been computed as sum of share capital and reserves and surplus.*
3. *NAV is computed as the closing net worth divided by the closing outstanding number of equity shares adjusted for corporate actions, if any.*

3. Weighted Average return on net worth for the last 3 FYs, and return on net worth for any interim period for the issuer company.

Financial Year/Period	Return on Net Worth (%)	Weights
Financial Year ended March 31, 2025	43.27	3
Financial Year ended March 31, 2024	49.28	2
Financial Year ended March 31, 2023	(96.12)	1
Weighted Average	**22.04**	**6**
For the Stub Period ended on June 30, 2025*	**12.64**	

** Not Annualized*

Notes:

1. *Weighted Average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. sum of (RoNW × Weight) for each year / Total of weights;*
2. *The figures disclosed above are based on the Restated Financial Statements of our Company.*
3. *Net worth, as restated at the end of the relevant financial year/period, is equity attributable to the owners of the Company.*

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI, as applicable.
The Price per share of our Company based on the primary / new issue of shares (equity / convertible securities).

a) The Price per share of our Company based on the primary/ new issue of shares (equity / convertible securities).
There has been no issuance of Equity Shares during the 18 months preceding the date of the Red Herring Prospectus (Except Bonus Issue of Shares), where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days.

b) The price per share of our Company based on the secondary sale / acquisition of shares (equity / convertible securities).
There have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

c) Price per share based on the last five primary or secondary transactions;
Since there are no transactions to report to under (a) and (b) therefore, information based on last 5 secondary transactions (primary transactions and secondary transaction where Promoter / Promoter Group entities or shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), not older than 3 years prior to the date of this Red Herring Prospectus irrespective of the size of transactions is required to be disclosed. Details of the same is provided below:

Primary Transaction:

Date of Issue	Nature of Allotment	Names of Person	Number of Shares Allotted	Issue Price
February 24, 2025	Bonus Allotment	Mr. Devendra Singh Yadav	84,00,000	0.00
		Mrs. Asha Yadav	5,00,000	
		Mr. Nitin Kumar	5,00,000	
		Mrs. Deepali Yadav	5,00,000	
		Mrs. Sunita Yadav	99,980	
		Mr. Garvit Garg	10	
		Mr. Pulkit Garg	10	
	TOTAL		**1,00,00,000**	**0.00**
	Weighted Average Cost of Acquisition (WACA)			**0.00**

d) Weighted average cost of acquisition, floor price and cap price:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Floor Price i.e. ₹ 85/-	Cap Price i.e. ₹ 90/-
Weighted average cost of acquisition of primary / new issue as per paragraph a above.	N.A.	N.A.	N.A.
Weighted average cost of acquisition for secondary sale / acquisition as per paragraph b above.	N.A.	N.A.	N.A.
Weighted average cost of acquisition of primary issuances / secondary transactions as per paragraph 8(c) above: - Primary Transaction - Secondary Transaction	0.00 N.A.	0.00 N.A.	0.00 N.A.

Justification for Basis of Issue price: -

The following provides a detailed explanation for the Issue Price/Cap Price being 0.00 times of weighted average cost of acquisition of Equity Shares that were issued by our Company or acquired or sold by our Promoter, Promoter Group, or other shareholders with rights to nominate directors on our Board by way of primary and secondary transactions in the last three full Calendar Years preceding the date of the Red Herring Prospectus compared to our Company's KPIs/ financial ratios for the Calendar Years 2025, 2024 and 2023 and in view of external factors, if any.

- The Indian healthcare sector renowned for its dynamic growth potential and diverse components was estimated to value at an impressive USD 216 billion in FY23. This sector is projected to nearly double to an estimated USD 454 billion by FY28, representing a robust compound annual growth rate of 16%.
- The revenue growth from FY 2023 to FY 2025 reflects a compounded annual growth rate (CAGR) of 11.47%.
- The Price Band is ₹ 85 to ₹ 90 per Equity share has been determined by our Company, in consultation with the BRLM, on the basis of the demand from investors for the Equity Shares through the Book Building process. Investors should read the abovementioned information along with *"Risk Factors"*, *"Business Overview"* and *"Summary of Financial Information"* beginning on pages 23, 108, and 47 respectively of the Red Herring Prospectus, to have a more informed view.

Continue From Next Page...

Continue From Previous Page...

ADDITIONAL INFORMATION FOR INVESTORS: This will include the following:

1. Details of proposed /undertaken pre-issue placements from the DRHP filing date: Not Applicable.
2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date: Not Applicable.
3. ***Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company.***

	Pre-Issue shareholding as at the date of Advertisement			Post-Issue shareholding as at Allotment			
	Shareholders	Number of Equity Shares	Shareholding (in%)*	At the lower end of the price band (₹ 85/-)		At the upper end of the price band (₹ 90/-)	
				Number of Equity Shares	Share holding (in%)#	Number of Equity Shares	Share holding (in %)#
Promoters:							
1.	Mr. Devendra Singh Yadav	92,40,000	84.00	92,40,000	61.20	92,40,000	61.20
	Mrs. Deepali Yadav	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mrs. Asha Yadav	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mr. Jitendra Singh	Nil	Nil	Nil	Nil	Nil	Nil
	TOTAL A	**1,03,40,000**	**94.00**	**1,03,40,000**	**68.48**	**1,03,40,000**	**68.48**
Promoter's Group:							
2.	Mr. Nitin Kumar	5,50,000	5.00	5,50,000	3.64	5,50,000	3.64
	Mrs. Sunita Yadav	1,09,978	1.00	1,09,978	0.73	1,09,978	0.73
	TOTAL B	**6,59,978**	**6.00**	**6,59,978**	**4.37**	**6,59,978**	**4.37**
	Total Promoters and Promoter Group Shareholding (A+B)	**1,09,99,978**	**99.99**	**1,09,99,978**	**72.85**	**1,09,99,978**	**72.85**
Top 10 shareholders (Other than Promoters and Promoter Group)							
1.	Mr. Garvit Garg	11	Negligible	11	Negligible	11	Negligible
2.	Mr. Pulkit Garg	11	Negligible	11	Negligible	11	Negligible
3.	Public in IPO	-	-	40,99,200	27.15	40,99,200	27.15
	TOTAL C	**22**	**0.00**	**40,99,222**	**27.15**	**40,99,222**	**27.15**
	TOTAL (A+B+C)	**1,10,00,000**	**100.00**	**1,50,99,200**	**100.00**	**1,50,99,200**	**100.00**

**As a % of Pre-Issued Capital*
#As a % of Post Issued Capital

Notes:

1. *The Promoter Group shareholders are as mentioned in Point No.02*
2. *Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.*
3. *Based on the Issue price of ₹ [•] and subject to finalization of the basis of allotment.*

BASIS FOR THE ISSUE PRICE

The ***"Basis of the issue price"*** on page 86 of the offer document has been updated with the above price band. Please refer to the website of the BRLM for the "Basis of the issue price" updated with the above price band. You can scan the QR code given on the first page of this advertisement for the chapter titled ***"Basis for the Issue Price"*** on page 86 of the Red Herring Prospectus.

INDICATIVE TIMELINE FOR THE ISSUE

Submission of Bids (Other than Bids from Anchor Investors)
• No investor shall be permitted to bid at cut off price. • No investor shall be permitted downgrade, modification and cancellation of their bids.

BID / ISSUE PROGRAM

Anchor Investor Bidding Date		Tuesday, December 30, 2025	
Bid Opening Date	**Wednesday, December 31, 2025**	**Initiation of Unblocking of Funds/refunds (T +2 Days)**	**On or before Tuesday, January 06, 2026**
Bid Closing Date (T day)	**Friday, January 02, 2026**	**Credit of Equity Shares to demat accounts of Allotees (T +2 Days)**	**On or before Tuesday, January 06, 2026**
Finalization of basis of allotment with the Designated Stock Exchange/ Allotment of Securities (T +1 Day)	**Monday, January 05, 2026**	**Commencement of Trading of Equity Shares on the Stock Exchanges/Listing Date (T + 3 Days)**	**On or before Wednesday, January 07, 2026**

Timelines for Submission / Uploading of Application/Bid

Application Submission by Investors

- For all physical applications: Between 10.00 a.m. and 5.00 p.m. during Issue Period (except the Bid Closing Date).
- Electronic Applications (Online ASBA through 3-in-1 accounts): Up to 4.00 p.m. on Bid Closing Date i.e. T day.
- Electronic Applications (Bank ASBA through online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA, etc.): Up to 3.00 p.m. on Bid Closing Date i.e. T day.
- Electronic Applications (Syndicate Non-Retail, Non-Individual Applications): Up to 3.00 p.m. on Bid Closing Date i.e. T day.
- Physical Applications (Bank ASBA): Up to 1.00 p.m. on Bid Closing Date i.e. T Day.
- Physical Applications (Syndicate Non-Retail, Non-Individual Applications of QIBs and NIIs): Up to 12.00 p.m. on Bid Closing Date i.e. T Day and Syndicate members shall transfer such applications to banks before 1.00 p.m. on Bid Closing Date i.e. T Day.
- On the Bid Closing Date, the Bids shall be uploaded until 4.00 p.m. for all Bidders.
- Bid modification: From Issue Opening Date up to 4.00 p.m. on Bid Closing Date i.e. T Day.
- UPI mandate acceptance/confirmation end time shall be at 5.00 p.m. on the Issue/Bid Closing Date.

Above information is only for reference purpose only and may change from bank to bank and broker to broker. Investors are requested to contact their own bank/broker for specific details.

ASBA* | **Simple, Safe, Smart way of Application- Make use of it!!!** | ***Applications Supported by Blocked Amount (ASBA) is a better way of applying to issue by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below. Mandatory in Public Issues No cheque will be accepted.**

UPI - UNITED PAYMENTS INTERFACE

UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to Rs. 500,000**
Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. "ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 222 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.
**ASBA forms can be downloaded from the website BSE and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in.*
***List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. IndusInd Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll-free number-18001201740 and Mail Id- ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in.*

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS:
For information on the main objects and other objects of our Company, see *"History and Corporate Structure"* on page 139 of the Red Herring Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section *"Material Contracts and Documents for Inspection"* on page 284 of the Red Herring Prospectus.

LIABILITY OF MEMBERS OF THE COMPANY: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorised share capital of the Company is ₹ 17,00,00,000 divided into 1,70,00,000 Equity Shares of face value of ₹ 10/- each. The issued, subscribed and paid-up share capital of the Company before the Issue is ₹ 11,00,00,000 divided into 1,10,00,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see "Capital Structure" on the page 60 of the Red Herring Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Mr. Devendra Singh Yadav – 5000 and Mrs. Asha Yadav – 5000. For details of the Capital Structure, see "Capital Structure" on the page 60 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus/ Prospectus will be filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 202 of the RHP.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited ("BSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by BSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to page 203 of the Red Herring Prospectus for the full text of the Disclaimer clause pertaining to BSE.

CREDIT RATING: This being the issue of Equity Shares, no credit rating is required.

DEBENTURE TRUSTEE: This being the issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since this issue is made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading Agency.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of our Company and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to 'Risk Factors' on page 23 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
BEELINE	MUFG	MODERN Diagnostic & Research Centre
BEELINE CAPITAL ADVISORS PRIVATE LIMITED **SEBI Registration Number:** INM000012917 **Address:** B 1311-1314, Thirteenth Floor, Shilp Corporate Park, Rajpath Rangoli Road, Thaltej, Ahmadabad-380054, Gujarat, India. **Telephone Number:** 07948407357 **Email Id:** mb@beelinemb.com **Investors Grievance Id:** ig@beelinemb.com **Website:** www.beelinemb.com **Contact Person:** Mr. Nikhil Shah **CIN:** U67190GJ2020PTC114322	**MUFG Intime India Private Limited (Formerly Link intime India Private Limited)** **SEBI Registration Number:** INR000004058 **Address:** C 101, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, India **Tel. No.:** +91-22-4918 6000/ +91 8108114949 **Email Id:** moderndiagnostic.smeipo@in.mpms.mufg.com Investors Grievance Id: moderndiagnostic.smeipo@in.mpms.mufg.com **Website:** www.linkintime.co.in **Contact Person:** Shanti Gopalkrishnan **CIN:** U67190MH1999PTC118368	**MODERN DIAGNOSTIC & RESEARCH LIMITED** Mrs. Priyanshu Yadav **Registered Office:** Plot No H-64,1st Floor BLK-H, Bali Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India **Corporate Office:** 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Telephone No:** +91- 9999474297 **E-Mail:** compliance@mdrcindia.com **Website:** www.mdrcindia.com Investors can contact the Company Secretary and Compliance Officer or the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE Limited i.e. www.bseindia.com, respectively.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE Limited i.e. www.bseindia.com, respectively.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered and Corporate Office of the Company: Modern Diagnostic & Research Centre Limited, Telephone: +91 9999474297; BRLM: Beeline Capital Advisors Private Limited, Telephone: +91-7948407357 and the Syndicate Member: Spread X Securities Private Limited; Telephone: +91 79 69072020 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of BSE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

SYNDICATE MEMBER: Spread X Securities Private Limited

BANKER TO THE ISSUE/ ESCROW COLLECTION BANK AND REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: IndusInd Bank Limited.

SPONSOR BANKS: IndusInd Bank Limited..

UPI: UPI Bidders can also bid through UPI mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

On behalf of Board of Directors
For, Modern Diagnostic & Research Centre Limited
sd/-
Mr. Devendra Singh Yadav
Chairman cum Managing Director

Place: Delhi
Date: December 23, 2025

Disclaimer: Modern Diagnostic & Research Centre Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the RHP with the Registrar of Companies, Delhi on December 23, 2025 and thereafter with SEBI and the Stock Exchanges. The RHP is available on the websites of SEBI at www.sebi.gov.in, website of the Company at www.mdrcindia.com, the website of the BRLM to the Issue at www.beelinemb.com, the website of BSE SME i.e. www.bseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 23 of the Red Herring Prospectus.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being Offered and sold outside the United States in 'offshore transactions' in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such Offers and sales are made. There will be no public offering in the United States.

बड़ौली में घर तोडने.का आदेश मुगलों और अंग्रेजों से भी ज्यादा खतरनाक : डॉ. ऋषिपाल मास्टर

किशोर शर्मा / गुड़गांव मेल

फरीदाबाद, 22 दिसम्बर। फरीदाबाद के गुर्जर बाहुल्य गांव बड़ौली में हुई महापंचायत चौधरी बीरपाल गुर्जर बढ़ौली के संयोजन में आयोजित किया गया। पंचायत की अध्यक्षता चौधरी रणबीर चंदीला ने की। पंचायत को संबोधित करते हुए मास्टर ऋषिपाल ने कहा कि बड़ौली गांव में जोकि 900 साल पुराना गांव है और बहुत ही देशभक्तों और कदीमी हिन्दुस्तानियों का काम है उसमें मकानों को तोडने.का आदेश मुगलों और अंग्रेजों से भी ज्यादा खतरनाक और घटिया हैं। मास्टर ऋषिपाल ने हजारों की संख्या में आए लोगों को संबोधित करते हुए कहा कि आज हरियाणा में गुर्जर बिरादरी के कई विधायक, मंत्री और केंद्रीय मंत्री हैं। उसके बाद पूरे हरियाणा में सैकड़ों पार्षद हैं फिर भी अगर गुर्जर बिरादरी के साथ इतना बड़ा न्याय हो रहा है तो इसका मतलब साफ है किया तो इसमें कोई बहुत बड़ा लेन-देन है। मास्टर ऋषिपाल ने कहा की दूसरी बात ये भी हो सकती है कि सरकार इनकी मानती न हो। इनकी चलती न हो तो फिर ऐसी राजनीतिक ताकत और रुतबे का क्या फायदा जो अपनों का ही भला ना कर सके तो दूसरे उससे क्या आशा कर सकते है। मास्टर ने कहा कि सरकार का काम लोगों की भलाई लोगों के हितों की भलाई लोगों को अच्छे से बसाना। उसमें सुविधाएं देना होता है ना की लोगों को उजाडना उनको बर्बाद करना और उन्हें रोड पर खड़ा कर देना होता है। मास्टर ऋषिपाल ने जोर देकर कहा कि सरकार किसी भ्रम में न रहे अगर किसी मकान की एक भी ईंट तोड़ी तो सरकार की जनता ईंट सीट बजा देगी। उन्होंने कहा कि पता नहीं सरकार को गुर्जर बिरादरी के लोगों से क्या दिक्कत है जबकि सबसे ज्यादा वोट गुर्जर बिरादरी ने भाजपा को दिए हैं

फिर भी कभी अनंगपुर, कभी मेवला महाराजपुर, कभी अनखीर, कभी बढक्कल, कभी भतोला, कभी प्रहलादपुर और अब बढ़ौली में ही अधिकतर तोडफ़ोड़ हो रही है जबकि इतिहास इस बात का गवाह है कि दिल्ली के आसपास जब राजा अनंगपाल तोमर ने दिल्ली बसाई थी तो सबसे ज्यादा गुर्जर और जाट ही दिल्ली के आसपास बस आए थे तो फिर ये इस दायरे में कैसे आ गए कि मकानों को और जमीनों को अवैध बताया जा रहा है।

उन्होंने कहा इसका एक ही कारण है कि ये जमीन अब बहुत ही कीमती हो चुकी है और कुछ बिल्डरों की इस पर टेडी निगाह है कि इसको कैसे ही कब्जे में करके इससे मोटा पैसा कमाया जा सके।

मास्टर ऋषिपाल ने कहा कि किसी को धोखे में नहीं रहना चाहिए कि वो लोगों को अपनी सुविधा अनुसार उजाड़ देंगे और मोटे पैसे बनाने के लिए लोगों को बर्बाद कर देंगे तो समाज को अपनी रक्षा करनी आती है और अपनी संपतति की भी रक्षा करनी आती है। सरकार समाज को कमजोर न समझे। किसी भी हालत में समाज इस तरह से लोगों को उजडने. नहीं देगा। इसके लिए चाहे कोई भी कुर्बानी देनी पड़े। उन्होंने सख्त लहजे में कहा कि अगर कल को कोई हिंसा का आन्दोलन होता है तो इसकी जिम्मेदारी सरकार की रहेगी। लोगों की नहीं क्योंकि संविधान भी इस बात की आजादी देता है कि आदमी किसी भी हद तक जाकर अपने जानमाल की रक्षा कर सकता है। इस मौके पर मुख्य रूप से पूर्व सांसद चौधरी अवतार सिंह भड़ाना, ठाकुर पूरन सिंह सहारनपुर, चौधरी अंतराम तंवर, चौधरी रिंकू चंदीला, लखन सिंगला, गिरीश भारद्वाज, कपिल गुर्जर, रचना शर्मा आदि सैंकड़ों नेता उपस्थित रहे।